MedTrace Logo

TAXUS PERSEUS Workhorse

NCT00484315 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1264

Last updated 2014-05-08

Study results available
· View outcomes & findings →

Summary

The purpose of the TAXUS PERSEUS Workhorse trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo atherosclerotic lesions of up to 28 mm in length in native coronary arteries of 2.75 mm to 4.0 mm diameter.

Conditions

Interventions

DEVICE

Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation

TAXUS Element stent placement

DEVICE

Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement

TAXUS Express Stent Implant

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Dean J Kereiakes, MD · The Christ Hospital

  • Louis A Cannon, MD · Cardiac and Vascular Research Center of Northern Michigan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2009-09-30
Completion
2013-10-31

Countries

  • United States
  • Australia
  • New Zealand
  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00484315 on ClinicalTrials.gov